138 related articles for article (PubMed ID: 6559107)
1. Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.
Baker PJ; Parker CJ; Osofsky SG
Clin Exp Immunol; 1984 Jan; 55(1):166-76. PubMed ID: 6559107
[TBL] [Abstract][Full Text] [Related]
2. Complement 1 inhibitor is a regulator of the alternative complement pathway.
Jiang H; Wagner E; Zhang H; Frank MM
J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
[TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of a low molecular weight complement inhibitor present in normal human serum.
Baker PJ; Osofsky SG
Clin Exp Immunol; 1981 Mar; 43(3):549-56. PubMed ID: 6912799
[TBL] [Abstract][Full Text] [Related]
4. New synthetic inhibitor to the alternative complement pathway.
Ikari N; Sakai Y; Hitomi Y; Fujii S
Immunology; 1983 Aug; 49(4):685-91. PubMed ID: 6553561
[TBL] [Abstract][Full Text] [Related]
5. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
Parker CJ; Baker PJ; Rosse WF
J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the enhanced susceptibility of paroxysmal nocturnal hemoglobinuria erythrocytes to complement-mediated hemolysis initiated by cobra venom factor.
Parker CJ; Stone OL; Bernshaw NJ
J Immunol; 1989 Jan; 142(1):208-16. PubMed ID: 2909615
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
8. [Paroxysmal nocturnal hemoglobinuria. Increase in proteins of the alternative complement pathway].
de Gramont A; Kazatchkine M; Maillet F; Blanche M; Debray J
Presse Med; 1983 Mar; 12(12):747-50. PubMed ID: 6220312
[TBL] [Abstract][Full Text] [Related]
9. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
Parker CJ; White VF; Falk RJ
Complement; 1986; 3(4):223-35. PubMed ID: 3643079
[TBL] [Abstract][Full Text] [Related]
10. Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.
Pangburn MK; Schreiber RD; Trombold JS; Müller-Eberhard HJ
J Exp Med; 1983 Jun; 157(6):1971-80. PubMed ID: 6222136
[TBL] [Abstract][Full Text] [Related]
11. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the alternative pathway of complement by pH.
Fishelson Z; Horstmann RD; Müller-Eberhard HJ
J Immunol; 1987 May; 138(10):3392-5. PubMed ID: 2952717
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
Parker CJ; Wiedmer T; Sims PJ; Rosse WF
J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
[TBL] [Abstract][Full Text] [Related]
14. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum.
Edens RE; Linhardt RJ; Bell CS; Weiler JM
Immunopharmacology; 1994; 27(2):145-53. PubMed ID: 8014028
[TBL] [Abstract][Full Text] [Related]
15. Comparison of binding characteristics of factors B and H to C3b on normal and paroxysmal nocturnal hemoglobinuria erythrocytes.
Parker CJ; Baker PJ; Rosse WF
J Immunol; 1983 Nov; 131(5):2484-9. PubMed ID: 6226743
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of complement derived from the erythrocyte membrane in paroxysmal nocturnal hemoglobinuria.
Chua C; Hoffmann EM; Adams JP; Rosse WF
Blood; 1980 May; 55(5):772-6. PubMed ID: 7362868
[TBL] [Abstract][Full Text] [Related]
17. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
Kozlov LV; Soliakov LS; Zinchenko AA
Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
[TBL] [Abstract][Full Text] [Related]
18. Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
J Immunol; 2009 Dec; 183(11):7347-51. PubMed ID: 19890040
[TBL] [Abstract][Full Text] [Related]
19. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
[TBL] [Abstract][Full Text] [Related]
20. Control of immune complex and zymosan-mediated anaphylatoxin generation by proteins B and H of the alternative complement pathway.
Kings M; Nydegger UE; de Weck AL
Immunology; 1984 Jan; 51(1):123-31. PubMed ID: 6197357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
